17 results about "Immunological memory" patented technology

The invention provides a fusion protein vaccine and application thereof. Specifically, the invention provides a fusion protein and a pharmaceutical composition of the fusion protein and an STING agonist, and provides application of the pharmaceutical composition. According to the fusion protein vaccine disclosed by the invention, the titers of a specific neutralizing antibody and a binding antibody are remarkably improved, the broad spectrum and durability are enhanced, and the immune response of T cells is remarkably improved; besides, the fusion protein vaccine promotes the generation of memory T and B cells, effectively improves immune memory induced by the vaccine, provides a new strategy for preventing and / or treating diseases induced by respiratory tract infection, and has a wide application prospect.

The invention discloses a novel benzothiazole compound as well as a preparation method and application thereof. According to the novel benzothiazole compound, through targeted activation of an RIG-I / OAS innate immune pathway, expression of key proteins and genes such as OAS1 and RIG-I can be rapidly up-regulated, secretion of type I interferon and proinflammatory factors is induced, and instant immune enhancement is achieved; more importantly, by performing long-term functional reprogramming on innate immune cells (such as mononuclear cells and dendritic cells), persistent'innate immune memory '(namely immune domestication) can be induced. The dual-action mechanism can significantly enhance the activation of antigen presenting cells and promote the generation and long-term maintenance of memory B cells and effector memory T cells, has no significant toxicity to liver functions, can be used as an immunologic adjuvant and an immunodomestication molecule of an RSV vaccine, can synergistically improve the vaccine-induced RSV specific antibody titer and neutralizing antibody level, and can be used for preparing an immunologic adjuvant for the RSV vaccine. Long-acting immune protection is provided, and a brand new solution is provided for research and development of RSV vaccines.

The invention belongs to the field of catalytic materials, and particularly relates to a metal titanium-based biological catalytic material as well as a preparation method and application thereof. The invention provides a metallic titanium-based biological catalytic material which is prepared by the following steps: adsorbing iridium in TiN nanoparticles by adopting a solvent impregnation method, and then carrying out heat treatment to prepare an Ir cluster doped TiN acanthosphere-shaped metallic titanium-based biological catalytic material, namely Ir-TiN. The Ir-TiN prepared by the invention shows excellent POD enzyme-like reaction kinetics: the maximum reaction rate (Vmax) is 5.7339 M s <-1 >, the conversion number (TON) is 88.73 s <-1 >, and the Ir-TiN has excellent ROS catalytic activity and near-infrared light response performance. Experiments show that the Ir-TiN has excellent bacterium removal capability and healing promotion capability on MRSA infected skin wounds, and can activate immune cells of an organism to establish immune memory so as to cope with reinfection.

The invention discloses a mycobacterium tuberculosis mRNA (messenger Ribonucleic Acid) vaccine as well as a construction method and application thereof, and belongs to the technical field of biological medicines. The technical problem to be solved is to provide a novel mycobacterium tuberculosis mRNA vaccine which is low in dosage, high in safety and lasting in immune memory. According to the technical scheme, the preparation method is characterized by comprising the following steps: carrying out tandem expression on antigens for coding Hsp65 and Mpt83, constructing mRNA molecules by combining tPA signal peptide (SEQ ID NO: 1), an MITD sequence (SEQ ID NO: 5) and flexible Linker (SEQ ID NO: 6-7), and carrying out codon optimization (an mRNA secondary structure and GC content) and a lipid nanoparticle (LNP) encapsulation process to finally obtain the novel mycobacterium tuberculosis mRNA vaccine.

The application discloses a recombinant virus-like nanoparticle for immunotherapy of gastric cancer and application thereof. The recombinant virus-like nanoparticle is a chimeric recombinant virus-like nanoparticle formed by self-assembly of a fusion protein HBC-CLDN18.2 of a hepatitis B virus core protein and CLDN18.2 tight junction protein. The application uses genetic engineering technology to truncate the C-terminal end of a natural hepatitis B virus core antigen, and mutate cysteine residues at positions 48 and 107 into serine, so that the hepatitis B virus core antigen can self-assemble into a virus-like nanoparticle with strong stability. The virus-like nanoparticle is used as a carrier, a B cell epitope peptide (tight junction protein CLDN18.2) of a gastric cancer tumor-related antigen is inserted into an immunodominant site of the carrier, so that the humoral immune response against gastric cancer is enhanced. Two T cell epitope peptides of the heterologous hepatitis B virus core antigen are used to replace T cell epitope peptides on the carrier, so that the cellular immune response against gastric cancer is enhanced, and strong antitumor effect and immune memory effect are shown.

This invention provides a method for isolating, culturing, activating, and applying NK cells in tumor immunology. The method includes isolating monocytes from peripheral blood of healthy adults, removing non-NK cell populations using negative selection, and enriching and purifying NK cells. Through stimulation with specific cytokines, NK cells are successfully expanded and their cytotoxicity is activated. This invention optimizes the preparation and activation methods of NK cells, obtaining NK cells with highly efficient cytotoxic activity in vitro, and significantly improving tumor treatment efficacy when used in combination with immune checkpoint inhibitors. Combining the immune memory effect of NK cells, this invention provides a novel anti-tumor immunotherapy method and can be applied to the preparation of new anti-tumor drugs, offering innovative ideas for tumor treatment.

The invention discloses a mineralized foot-and-mouth disease virus-like particle hydrogel vaccine as well as a preparation method and application thereof. The hydrogel vaccine is obtained by taking a mixture of hyaluronic acids with medium, high and low molecular weights as a carrier and entrapping calcium phosphate mineralized foot-and-mouth disease virus-like particles. The safety of the hydrogel vaccine is comprehensively evaluated through in-vivo and in-vitro experiments, and the result shows that the hydrogel vaccine constructed by the invention has excellent biocompatibility. Meanwhile, the hydrogel vaccine shows excellent antigen slow release ability, can induce generation of a specific antibody level equivalent to that of a VLPs-CaP vaccine compatible with an ISA201 adjuvant, and can also significantly improve the expression level of surface molecules of lymphatic B cell memory and T cell memory. The results show that the hydrogel vaccine constructed by the invention can induce excellent humoral immune response, cellular immune response and immune memory level, and has a good application prospect in the field of veterinary vaccines.

This invention discloses a wave power generation control system based on an immune genetic algorithm. The outer loop control loop includes: an immune memory bank, a nonlinear error feedback control law, a primary dual-buoy object, a secondary dual-buoy object, and a mirror image of the secondary buoy object. The inner loop control loop includes: a vertical velocity control module and a process model. The output of the mirror image of the secondary buoy object is connected to the input of the nonlinear feedback control law. The output of the nonlinear error feedback control law is connected to the input of the vertical velocity control module. The output of the vertical velocity control module is connected to the input of the process model, the input of the secondary dual-buoy object, and the input of the mirror image of the secondary dual-buoy object. The output of the secondary dual-buoy object is connected to the input of the primary dual-buoy object. The output of the process model is connected to the input of the vertical velocity control module. This invention solves the problem of interference from unmeasurable state variables, optimizes the wavelength and wave height of the waves, and improves the stability of the system.

The invention provides a vaccine adjuvant, a protein used by the vaccine adjuvant and a preparation method of the protein. The technical problem to be solved is how to provide an effective and nontoxic vaccine adjuvant. The invention discloses a protein. The protein is any one of the following items: A1) a protein with an amino acid sequence as shown in a sequence 2; a2) a protein which is obtained by substitution and / or deletion and / or addition of amino acid residues of the protein in A1), has 80% or more of identity with the protein in A1) and has the same function as the protein in A1); and A3) a fusion protein obtained by connecting the N terminal or / and C terminal of A1) or A2) with a protein tag. The invention discloses an influenza virus adjuvant which is named as protein Ad-20, and the protein Ad-20 serving as the influenza virus adjuvant can stimulate humoral immunity and cellular immunity, has the functions of stimulating maturation of B cells and promoting the B cells to secrete antibodies in advance, is used for enhancing immunogenicity and immune memory of virus vaccines, is non-toxic and has the effect higher than that of an aluminum adjuvant; and a new auxiliary means is provided for research and development of effective vaccines.

The present invention relates to a dual treatment of tumor matrix binding IL-7 and IL-12 variants that produces synergistic anti-tumor efficacy by inhibiting immune depletion and promoting immune memory without compromising tolerance. The present disclosure describes polypeptides comprising an IL-7 polypeptide or a functional fragment thereof linked to an extracellular matrix ECM-affinity domain. Nucleic acids encoding the polypeptides of the disclosure and cells comprising the polypeptides or nucleic acids of the disclosure are also described.

The present application relates to the field of nanobiomaterials, in particular to a drug-loaded nanovaccine and a preparation method and application thereof, so as to improve tumor treatment effect and biological safety. The drug-loaded nanovaccine comprises MIL-100(Fe) and a manganese-doped mesoporous silica carrier, the MIL-100(Fe) is coated on the outer surface of the manganese-doped mesoporous silica carrier, and the manganese-doped mesoporous silica carrier is loaded with sorafenib. The MF@SOR nanovaccine of the present application has very high biological safety. Meanwhile, the carrier of the present application is wrapped with a layer of MIL-100(Fe), the coating is very uniform and stable, which can further improve the bioavailability of sorafenib, maximize the use of drugs and reduce the toxic and side effects of drugs. In addition, the MF@SOR nanovaccine can also induce the body to produce immune memory, inhibit the recurrence and metastasis of tumors, the recurrence and metastasis of tumors are significantly reduced, and the treatment effect of tumors is significantly improved.

The present application provides a preparation method for a fragmented tumor antigen. The method comprises: acquiring a tumor cell suspension; and irradiating and incubating the tumor cell suspension to prepare a fragmented tumor antigen. The preparation method of the present application is simple and has a low cost and storage convenience. A fragmented tumor antigen prepared by the preparation method of the present application can significantly inhibit tumor growth in vivo after being inoculated into an individual, can also effectively inhibit metastasis and recurrence of a tumor, induces the generation of immunological memory for a continuous anti-tumor effect, and significantly improves the control of a metastatic tumor. The fragmented tumor antigen prepared by the present application, either alone or in combination, can exert an effective anti-tumor effect in vivo.

The invention belongs to the technical field of biological medicines, and discloses an immune checkpoint blocking therapy for targeted NKT cells. The platform comprises a hollow mesoporous MnO2 nano catalytic core, a glutamine metabolism regulator PRCG loading layer and surface CD1d-alpha-GalCer compound modification, and through high active oxygen in-situ removal, pH / H2O2 responsive drug release and NKT cell specific targeting, the metabolic activity and the anti-tumor function of the platform are synergistically recovered. The core bottleneck problem of metabolic dysfunction caused by high active oxygen level of NKT cells in a tumor microenvironment is successfully solved by constructing a multifunctional nano-platform integrating targeted recognition, in-situ catalysis and metabolic reprogramming, the oxidative stress in the cells is remarkably reduced, ATP generation and IFN-gamma secretion are improved, and the tumor microenvironment is improved. The tumor suppression effect and the immune memory are enhanced when the polypeptide is combined with a PD-1 antibody, and the polypeptide has good biological safety.

The invention belongs to the technical field of immune cell therapy, and particularly relates to a chimeric antigen receptor T cell for expressing HPSE-pX-delta 1-30 and application of the chimeric antigen receptor T cell. According to the invention, HPSE-pX-delta 1-30 is expressed through engineered CAR T cells, and the activity of HPSE is limited to TME by using an exosome, so that systematic off-target toxicity is avoided. The result of the embodiment shows that the CAR T cell has remarkable ECM infiltration capacity, tumor killing efficiency and lasting immune memory phenotype, has the characteristics of simplicity in preparation, high safety and remarkable curative effect, and can be used for preparing medicines for treating solid tumors rich in ECM.

This invention discloses an injectable composite hydrogel adjuvant, its preparation method, and its application. The composite hydrogel adjuvant is formed by conjugating the TLR receptor 7 agonist Gardimquid to chitosan oligosaccharide, and then adding the Gardimquid-conjugated chitosan oligosaccharide to an oxidized hyaluronic acid solution, forming a stable gel through chemical cross-linking. This composite hydrogel adjuvant is loaded with calcium phosphate-mineralized type O foot-and-mouth disease virus-like particles to form a hydrogel vaccine. Experimental results show that the vaccine has excellent biocompatibility, recruiting 16.12% dendritic cells and 9.62% macrophages (antigen-presenting cells), and has the ability to enhance antigen migration and uptake, and promote immune cell activation. Furthermore, it can induce sustained and potent levels of specific antibodies and cellular immunity, and maintain immune memory for 20 weeks. This invention provides an effective technical means to improve the duration of immunity from foot-and-mouth disease virus-like particles, enhance the immunization effect, and achieve single-dose immunization.

The invention relates to a construction method of an animal model, in particular to a construction method of an embryonic antigen specificity CD8 + T cell mediated mouse recurrent abortion model. The OT-1 cells are adoptively transferred in vivo, immune memory is induced to be generated, and the OT-1 cells are combined with an Act-mOVA male mouse, so that the recurrent abortion process mediated by the embryonic antigen specific CD8 + T cells is successfully simulated. The animal model construction method is novel, safe and reliable, the modeling success rate and modeling efficiency are improved, meanwhile, the embryo antigen specific CD8 + T cell mediated mouse recurrent abortion model is proposed for the first time, the model mouse abortion reason is clear, relevant research on embryo antigens and antigen specific CD8 + T cells in the industry is facilitated, and the method has good application prospects.

The application provides an antibody or fragment thereof of an activation receptor (OX40) expressed on the surface of activated CD4+ T and CD8+ T cells, and use of the antibody or fragment thereof for preventing or treating diseases. The antibody of the application has high affinity for OX40, obvious effect of activating the OX40 signal pathway, relatively broad immune enhancement effect, and the ability of enhancing T cell response immune memory. In an animal model in vivo experiment, good tumor inhibition and killing effects are achieved, and the antibody has good clinical application prospect.